505 related articles for article (PubMed ID: 26280447)
41. Angiotensin Receptor-Neprilysin Inhibition.
Havakuk O; Elkayam U
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):356-364. PubMed ID: 28587583
[TBL] [Abstract][Full Text] [Related]
42. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
43. Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
Lin LM; Wu Y; Wu MF; Lin JX
Cardiovasc Drugs Ther; 2016 Dec; 30(6):623-633. PubMed ID: 27858191
[TBL] [Abstract][Full Text] [Related]
44. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338
[TBL] [Abstract][Full Text] [Related]
45. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
Vardeny O; Tacheny T; Solomon SD
Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
[TBL] [Abstract][Full Text] [Related]
46. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
King JB; Bress AP; Reese AD; Munger MA
Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
[TBL] [Abstract][Full Text] [Related]
47. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
Schoenfeld HA; West T; Verghese PB; Holubasch M; Shenoy N; Kagan D; Buono C; Zhou W; DeCristofaro M; Douville J; Goodrich GG; Mansfield K; Saravanan C; Cumin F; Webb RL; Bateman RJ
Toxicol Appl Pharmacol; 2017 May; 323():53-65. PubMed ID: 28315356
[TBL] [Abstract][Full Text] [Related]
48. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
[No Abstract] [Full Text] [Related]
49. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
Kario K; Sun N; Chiang FT; Supasyndh O; Baek SH; Inubushi-Molessa A; Zhang Y; Gotou H; Lefkowitz M; Zhang J
Hypertension; 2014 Apr; 63(4):698-705. PubMed ID: 24446062
[TBL] [Abstract][Full Text] [Related]
50. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
51. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
52. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
[TBL] [Abstract][Full Text] [Related]
53. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Mills J; Vardeny O
Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
[TBL] [Abstract][Full Text] [Related]
54. Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension.
Wang TD; Tan RS; Lee HY; Ihm SH; Rhee MY; Tomlinson B; Pal P; Yang F; Hirschhorn E; Prescott MF; Hinder M; Langenickel TH
Hypertension; 2017 Jan; 69(1):32-41. PubMed ID: 27849566
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Han Y; Ayalasomayajula S; Pan W; Yang F; Yuan Y; Langenickel T; Hinder M; Kalluri S; Pal P; Sunkara G
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):109-116. PubMed ID: 26961539
[TBL] [Abstract][Full Text] [Related]
56. Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug.
Gervasini G; Robles NR
Expert Opin Investig Drugs; 2017 May; 26(5):651-659. PubMed ID: 28388237
[TBL] [Abstract][Full Text] [Related]
57. Insights into implementation of sacubitril/valsartan into clinical practice.
Martens P; Beliën H; Dupont M; Mullens W
ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
[TBL] [Abstract][Full Text] [Related]
58. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
59. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Ayalasomayajula SP; Langenickel TH; Jordaan P; Zhou W; Chandra P; Albrecht D; Pal P; Rajman I; Sunkara G
Eur J Clin Pharmacol; 2016 Sep; 72(9):1065-73. PubMed ID: 27230850
[TBL] [Abstract][Full Text] [Related]
60. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
Mair J; Lindahl B; Giannitsis E; Huber K; Thygesen K; Plebani M; Möckel M; Müller C; Jaffe AS;
Eur Heart J Acute Cardiovasc Care; 2017 Jun; 6(4):321-328. PubMed ID: 26758541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
